US Stock MarketDetailed Quotes
CLNN Clene
- 0.3899
- -0.0015-0.38%
Close May 8 16:00 ET
- 0.3899
- 0.00000.00%
Post 18:13 ET
50.08MMarket Cap-829P/E (TTM)
0.4000High0.3666Low454.64KVolume0.3890Open0.3914Pre Close173.77KTurnover0.68%Turnover RatioLossP/E (Static)128.43MShares1.090052wk High3.75P/B26.06MFloat Cap0.250052wk Low--Dividend TTM66.85MShs Float17.8200Historical High--Div YieldTTM8.53%Amplitude0.2500Historical Low0.3820Avg Price1Lot Size
About Clene Company
Clene, Inc. is a clinical-stage biopharmaceutical company, which focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology therapeutics. It offers a nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. The company was founded in 2013 and is headquartered in Salt Lake City, UT.
Company Profile
SymbolCLNN
Company NameClene
Listing DateAug 27, 2018
Founded2013
CEOMr. Robert Etherington
MarketNASDAQ
Employees85
Securities TypeOrdinary Shares
Fiscal Year Ends12-31
Address6550 South Millrock Drive,Suite G50
CitySalt Lake City
ProvinceUtah
CountryUnited States of America
Zip Code84121
Phone1-801-676-9695
Websitehttp://www.clene.com
Company Executives
- Name
- Position
- Salary
- Robert Etherington
- President, Chief Executive Officer and Director
- 1.71M
- Mark Mortenson
- Chief Science Officer
- 1.38M
- Morgan R. Brown
- Chief Financial Officer and Principal Accounting Officer
- 993.70K
- David J. Matlin
- Chairman of the Board
- 139.93K
- Reed Neil Wilcox
- Director
- 294.25K
- Dr. Arjun JJ Desai, M.D.
- Independent Director
- --
- Alison H. Mosca
- Independent Director
- 123.39K
- Jonathon T. Gay
- Independent Director
- 96.13K
- Dr. Vallerie V. McLaughlin
- Independent Director
- 106.84K
- Matthew Kiernan
- Independent Director
- --
- Shalom Jacobovitz
- Independent Director
- 121.93K
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg